Onyx Pharmaceuticals Inc (ONXX.OQ)
134.40USD
1 Aug 2013
$3.10 (+2.36%)
$131.30
$131.48
$135.16
$131.48
489,722
449,242
$136.86
$66.40
About
Overall
| Beta: | 1.33 |
| Market Cap (Mil.): | $9,556.57 |
| Shares Outstanding (Mil.): | 72.74 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ONXX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -2.51 | -- | -- |
| ROI: | -11.63 | -2.58 | 18.76 |
| ROE: | -17.03 | -2.66 | 19.59 |
Amgen profit tops Wall Street view; rebounds from first quarter
- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.
UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr
July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.
Amgen profit tops Wall Street view; rebounds from first quarter
- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.
Exclusive: Amgen lines up BofA, JPM, Barclays to finance Onyx deal -sources
NEW YORK - Amgen Inc, the world's largest biotechnology company, has lined up Bank of America Corp, JPMorgan Chase & Co and Barclays Plc to finance a potential deal for Onyx Pharmaceuticals Inc, according to three people familiar with the matter.
Traders in Onyx in SEC insider case surface, claim innocence
NEW YORK - Two previously unnamed defendants have come forward in a U.S. Securities and Exchange Commission civil lawsuit over alleged insider trading in Onyx Pharmaceuticals Inc while the company was mulling a takeover bid, and said they did nothing wrong.
UPDATE 2-Traders in Onyx in SEC insider case surface, claim innocence
* Two Dubai traders say call options purchases were lawful
CORRECTED-UPDATE 1-Traders in Onyx in SEC insider case surface, claim innocence
(Corrects quotation in paragraph 10 to read "options trading" instead of "insider trading")
CORRECTED-Traders in Onyx in SEC insider case surface, claim innocence
(Corrects quotation in paragraph 5 to read "options trading" instead of "insider trading")
DEALTALK-Biotech takeover interest more fad than fashion
July 19 - Investors betting on a wave of big biotechnology deals following Amgen Inc's $10 billion bid for Onyx Pharmaceuticals Inc may well be disappointed.
Exclusive: Pfizer not moving forward with Onyx bid: sources
NEW YORK - Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker.
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,610 | +30.00 |
| Astellas Pharma Inc (4503.T) | ¥5,310 | -30.00 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

